Allogeneic blood transfusions involve complex biological products prepared from donated blood and are considered unique in many respects compared with other health care therapeutics. Blood donors are a demographically and genetically diverse group of individuals with inherited differences that may affect the stability of and outcomes associated with transfused blood components. Given the inherent variation in donated blood, most countries use a regulatory authority, such as the US Food and Drug Administration, to monitor factors associated with blood collection, manipulation, storage, and safety. Following significant advances in the reduction of infectious risks that have been associated with allogeneic blood transfusion during the past 2 decades, there has been a concerted effort to understand and improve the quality and potency of donated blood components. Recent efforts have been devoted to understanding the effect of blood processing methods, storage solutions, and duration of blood product storage on the quality of the product.
Roubinian N, Brambilla D, Murphy EL. Statistical Caution in Big Data Approaches to Transfusion Medicine Research. JAMA Intern Med. 2017;177(6):860–861. doi:10.1001/jamainternmed.2017.0914
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.